Medical Resource Utilization of Abiraterone Acetate Plus Prednisone Added to Androgen Deprivation Therapy in Metastatic Castration-Naive Prostate Cancer: Results From LATITUDE

Cancer - United States
doi 10.1002/cncr.31847
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Germline Variant in SLCO2B1 and Response to Abiraterone Acetate Plus Prednisone (AA) in New Onset Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

Mp52-11 Association of Dose Reduction of Abiraterone Acetate Plus Prednisone or Enzalutamide and Psa Progression in Veterans With Metastatic Castration Resistant Prostate Cancer

Journal of Urology
Urology
2018English

Phase II Pilot Study of the Prednisone to Dexamethasone Switch in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients With Limited Progression on Abiraterone Plus Prednisone (SWITCH Study)

British Journal of Cancer
Cancer ResearchOncology
2018English

A Prognostic Model for Stratifying Clinical Outcomes in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate

Canadian Urological Association Journal
Urology
2017English

Mp50-20 Impact of Abiraterone Acetate in Prostate Specific Antigen Trial Update: Effect of Abiraterone Acetate and Low Dose Prednisone on Prostate-Specific Antigen and Radiographic Disease Progression in Patients With Non-Metastatic Castration-Resistant Prostate Cancer

Journal of Urology
Urology
2016English

Cost-Effectiveness Analysis of Abiraterone, Docetaxel or Placebo Plus Androgen Deprivation Therapy for Hormone-Sensitive Advanced Prostate Cancer

Einstein (São Paulo, Brazil)
Medicine
2019English

Abiraterone Acetate and Docetaxel With Androgen Deprivation Therapy in High-Volume Metastatic Hormone-Sensitive Prostate Cancer in China: An Indirect Treatment Comparison and Cost Analysis

Cost Effectiveness and Resource Allocation
Health Policy
2019English

Pcn40 - A Retrospective Study on Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Prescribed Abiraterone Acetate + Prednisone Prior to Chemotherapy in Sweden, Norway and Denmark

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy